The majority of these inhibitors block auto-palmitoylation of key cysteine residues in TEADs, impact the ability of TEADs to bind to YAP, and/or block proliferation of cancer cells with Hippo pathway mutations (Bum-Erdene et al, 2019; Chan et al, 2016; Gibault et al, 2021; Gridnev et al, 2022; Holden et al, 2020; Hu et al, 2022; Kaneda et al, 2020; Laraba et al, 2023; Li et al, 2020; Lu et al, 2021; Lu et al, 2023; Lu et al, 2019; Noland et al, 2016; Pobbati et al, 2015; Sun et al, 2022; Tang et al, 2021). The gene discussed is YAP1; the disease is cancer.